UniQure announces key details of its planned trial to assess the safety and ability of AMT-130 gene therapy to lower the problematic huntingtin protein using a ‘single-shot’ virus delivery system.
Researchers design a virus to more effectively deliver gene-silencing drugs throughout the brain.